<DOC>
	<DOCNO>NCT03087773</DOCNO>
	<brief_summary>This study plan investigate impact Empagliflozin biomarkers heart failure patient myocardial infarction without type 2 diabetes mellitus within 6 month event .</brief_summary>
	<brief_title>Impact EMpagliflozin Cardiac Function Biomarkers Heart Failure Patients With Acute MYocardial Infarction</brief_title>
	<detailed_description>Type 2 diabetes mellitus ( T2DM ) associate two three-fold increase risk cardiovascular event compare subject without diabetes . Sodium-dependent glucose cotransporter 2 ( SGLT-2 ) mainly express human kidney small intestinal cell . In proximal tubule nephron SGLT-2 responsible reabsorption approximately 90 % filtrate glucose . Inhibition SGLT-2 show increase renal glucose excretion lower glucose . Subsequently , number SGLT-2 inhibitor develop currently approve treatment type 2 diabetes . Recently , Zinman B. et al publish result EMPA-REG-OUTCOME trial cardiovascular impact glucose lower regimen include Empagliflozin compare usual glucose control without SGLT-2 inhibitor investigate . The trial demonstrate unexpected reduction primary composite endpoint , comprise cardiovascular death , non-fatal myocardial infarction non-fatal stroke . The reduction mainly driven 38 % relative risk reduction cardiovascular death ; moreover demonstrate impressive 35 % relative risk reduction secondary endpoint hospitalization heart failure . Of note , beneficial effect observe Empagliflozin group seem occur rapidly commence treatment , suggest early separation Kaplan-Meier curve . However , mechanism responsible find remain unclear . Diuretic effect subsequent impact hemodynamics potential cardioprotective effect glucagon , level rise treatment SGLT-2 inhibitor result rise ketone body small increase hematocrit suggest . The aim trial investigate whether Empagliflozin treatment commence within 72-h acute myocardial infarction impact heart failure subject without diabetes mellitus type 2 .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>1 . Myocardial infarction evidence significant myocardial necrosis define rise creatinine kinase &gt; 1000 U/l troponin Tlevel ( troponin Ilevel ) &gt; 10x ULN . In addition least 1 follow criterion must meet : Symptoms ischemia ECG change indicative new ischemia ( new STT change new LBBB ) Imaging evidence new regional wall motion abnormality 2 . 18 75 year age 3 . Informed consent give write form 4. eGFR &gt; 45 ml/min/1.73m2 5 . Blood pressure first drug dose &gt; 110/70 mmHg 6 . â‰¤72h myocardial infarction 1 . Any form diabetes mellitus type 2 diabetes mellitus , history diabetic ketoacidosis 2 . Blood pH &lt; 7,32 3 . Known allergy SGLT2 inhibitor 4 . Haemodynamic instability define intravenous administration catecholamine , calcium sensitizer phosphodiesterase inhibitor 5 . &gt; 1 episode severe hypoglycaemia within last 6 month treatment insulin sulfonylurea 6 . Females child bear potential without adequate contraceptive method ( i.e . sterilisation , intrauterine device , vasectomised partner ; medical history hysterectomy ) 7 . Acute symptomatic urinary tract infection ( UTI ) genital infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>